Carfilzomib, lenalidomide, and dexamethasone improved progression-free survival (PFS) over... The ORR was 96%, including 92% at the level of VGPR, and the MRD negativity rate was 62%... In myeloma, isatuximab plus carfilzomib and dexamethasone (Isa-Kd) resulted in clinically improved... The median PFS with the three-drug combination was higher compared with carfilzomib and dexamethasone alone.